Diabetes and pancreatic cancer often go hand in hand. Between 30 to 50% of patients have diabetes or prediabetes at diagnosis, and another 40% develop it during treatment.

To get the latest information, host Alisyn Camerota is joined by endocrinologist and Director of the Duke Onco-Endocrinology Program at the Duke Center for Cancer Immunotherapy, Dr. Afreen Shariff, an Associate Director for the Cancer Therapy Toxicity Program and a member of the faculty in the Division of Endocrinology, Diabetes, and Metabolism at Duke University School of Medicine.

In this episode, Dr. Shariff discusses managing pancreatic cancer and diabetes, and how surgery, chemotherapy, and radiation can all affect blood sugar as a direct, on-target effect of treatment. She emphasizes working with an endocrinologist and oncologist to help control diabetes during and after treatment.

Her advice: get a clear diagnosis, know your numbers, and don't hesitate to bring up blood sugar concerns with your oncology team.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.

This episode is sponsored by Revolution Medicines.

For more information, visit letswinpc.org and pancan.org.

RESOURCES:

Let's Win's Diabetes Section
PancCAN Diabetes and Pancreatic Cancer
PanCAN Patient Services
Let's Win Doctor Finder
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder

Almost one in four people diagnosed with pancreatic cancer are also diagnosed with diabetes. In this episode of PancChat, host Alisyn Camerota talks with Dr. Suresh Chari, professor of medicine at MD Anderson Cancer Center and principal investigator for the PanCAN Early Detection Initiative, about the complex relationship between diabetes and pancreatic cancer.

Dr. Chari explains why new-onset diabetes can be an early warning sign for pancreatic cancer, why a sudden rise in blood sugar alongside unexplained weight loss is a pattern worth watching, and why early detection remains one of the biggest challenges in pancreatic cancer research. He also shares an update on the clinical trials underway — including AI-assisted imaging — aimed at catching pancreatic cancer earlier in people with new-onset diabetes.

This episode is sponsored by Revolution Medicines.

To learn more about pancreatic cancer support and resources, visit letswinpc.org and pancan.org.

Resources:

Let's Win Diabetes Info
PanCAN Diabetes Info
Let's Win Diabetes and Pancreatic Cancer Awareness Risk Quiz
PanCAN Patient Services
The Diabetes and Pancreatic Cancer Connection

With one new drug against the KRAS mutation on the path to FDA approval, what is the status of other KRAS drugs, as well as different types of treatment?

To get the latest information, host Alisyn Camerota is joined once again by Dr. Allyson Ocean, medical oncologist and director of the Pancreatic Cancer Research Program at Weill Cornell Medicine, and a co-founder of Let's Win, along with Dr. Anna Berkenblit, Chief Scientific and Medical Officer for PanCAN, who brings more than two decades of experience in the research and clinical development of novel anticancer therapies.

Together, they discuss the status of pancreatic cancer vaccine research, walk through what a drug's journey from idea to approval actually looks like, and explain in plain terms what separates a phase 1 clinical trial from a phase 2 or phase 3 trial — and why every phase matters for patients considering enrollment.

This episode is brought to you by our sponsor, Revolution Medicines.

To learn more about the latest breakthroughs in pancreatic cancer treatment, visit letswinpc.org and pancan.org.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.